secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRISTOL MYERS SQUIBB CO (BMY)
CIK:        0000014272
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001140361-22-006591
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BMY reports 2021 Abraxane net sales of $1.18B, triggers $4.5M CVR payment
-------------------------------------------------------------------------

- Abraxane net sales for 2021: $1,181,043,283 as recorded in BMY financial statements.
- Net Sales Payment to CVR holders: approximately $4,526,082, payable by March 7, 2022.
- Per CVR payment: approx $0.104592, based on record date March 6, 2022.
- Payment stems from CVRs assumed in 2019 Celgene acquisition under the CVR Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/14272/000114036122006591/0001140361-22-006591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/14272/000114036122006591/brhc10034437_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-006591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer